Zenas BioPharma, Inc.
ZBIO
$34.50
-$2.57-6.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -20.05% | 23.23% | |||
| Gross Profit | 20.05% | -72.70% | |||
| SG&A Expenses | 8.59% | -2.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.75% | 16.55% | |||
| Operating Income | 13.75% | -47.77% | |||
| Income Before Tax | 1.35% | -54.55% | |||
| Income Tax Expenses | -- | 109.76% | |||
| Earnings from Continuing Operations | 1.39% | -55.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.39% | -55.55% | |||
| EBIT | 13.75% | -47.77% | |||
| EBITDA | 13.75% | -47.83% | |||
| EPS Basic | 2.08% | -55.30% | |||
| Normalized Basic EPS | 11.55% | -54.32% | |||
| EPS Diluted | 2.08% | -55.30% | |||
| Normalized Diluted EPS | 11.55% | -54.32% | |||
| Average Basic Shares Outstanding | 0.70% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.70% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||